BioSpace News Archive

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the second quarter and first half of 2022 and provided a business update.

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time Recursion has been ranked by ISS.

Pasithea Therapeutics Corp. today announced it will present the preclinical proof of concept study results of its tolerizing vaccine program in multiple sclerosis (“MS”) on August 30th at the international conference “From Laboratory to Clinic: Medicine after COVID” held at Trinity College, Oxford University, United Kingdom.

Ybrain recently received the Translational Research Award at this year’s Neuroergonomics Conference and NYC Neuromodulation Conference held from July 28 to August 1 for its neuromodulation technology in transcranial direct current stimulation (tDCS).

Aligned Orthopedic Partners today announced a partnership with the Jordan-Young Institute, a specialized orthopedic practice with renowned physicians at the cutting edge of orthopedics, neurosurgery and physiatry.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that t:slim X2 insulin pump users have delivered more than 1 million insulin boluses using the t:connect app feature on their personal mobile device in the first month following its commercial release.

Woebot Health today announced that it has appointed Robbert Zusterzeel, M.D., Ph.D., M.P.H., as Vice President of Regulatory Science and Strategy.

On April 27, 2022, GyroStim became the first FDA-cleared device for treating balance disorders to receive FDA designation as a Breakthrough Device.

Bayer, a leader in women’s healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its market leading intrauterine device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg by one more year, making it available to prevent pregnancy for up to eight years.

NuvoAir, a digital health company focused on complex patients, initially targeting respiratory conditions, has shared results of its U.S. chronic obstructive pulmonary disease (COPD) pilot.